Nonaqueous, mini-dose glucagon for treatment of mild hypoglycemia in adults with type 1 diabetes: A dose-seeking study

Diabetes Care

Volumn 39, Issue 3, 2016, Pages 465-468

  Haymond, Morey W ^a   Redondo, Maria J ^a   McKay, Siripoom ^a   Cummins, Martin J ^b   Newswanger, Brett ^b   Kinzell, John ^b   Prestrelski, Steven ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Xeris Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCAGON; GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GASTROINTESTINAL AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MALE; MAXIMUM PLASMA CONCENTRATION; NONAQUEOUS PHASE LIQUID; TEMPERATURE MEASUREMENT; ANALYSIS; BLOOD; COMPLICATION; DRUG DELIVERY SYSTEM; INSULIN INFUSION; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; GASTROINTESTINAL AGENTS; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; RANDOM ALLOCATION;

EID: 84962109502     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2124     Document Type: Article

References (16)

1. Imura H, Nakao K, Shimatsu A, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:683-689
2. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-948
3. Frier BM. The incidence and impact of hypo-glycemia in type 1 and type 2 diabetes. International Diabetes Monitor 2009;21:210-218
4. Haymond MW, Schreiner B. Mini-dose glu-cagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001;24: 643-645
5. Chung ST, Haymond MW. Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. J Diabetes Sci Technol 2015;9:44-51
6. Onoue S, Iwasa S, Kojima T, et al. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J Chromatogr A 2006;1109:167-173
7. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944; 83:377-390
8. Westfall PH, Wolfinger RD. Multiple tests with discrete distributions. Am Stat 1997;51:3-8
9. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680
10. Tse TF, Clutter WE, Shah SD, Cryer PE. Mechanisms of postprandial glucose counterre-gulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J Clin Invest 1983;72:278-286
11. Ahrén B, Nobin A, Scherstén B. Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships. Acta Med Scand 1987;221:185-190
12. Martyn-Nemeth P, Schwarz Farabi S, Mihailescu D, Nemeth J, Quinn L. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for preventionda review. J Diabetes Complications. 7 September 2015 [Epub ahead of print]. DOI: 10.1016/j.jdiacomp.2015.09.003
13. Gonder-Frederick LA, Vajda KA, Schmidt KM, et al. Examining the Behaviour subscale of the Hypoglycaemia Fear Survey: an international study. Diabet Med 2013;30:603-609
14. Böhme P, Bertin E, Cosson E, Chevalier N; GEODE group. Fear of hypoglycaemia in patients with type 1 diabetes: do patients and di-abetologists feel the same way? Diabetes Metab 2013;39:63-70
15. American Diabetes Association. 6. Glycemic Targets. Diabetes Care 2015;38(Suppl. 1):S33-S40
16. Nakamura K, Walker T, Leach J, Bohnett L, Valdes J, Balo A. Incidence of hypoglycemia overtreatment in the SHARE Real Life Use Population. Late-breaking abstract presented at the 75th Annual Meeting of the American Diabetes Association, 5-9 June 2015, at the Boston Convention and Exhibition Center, Boston, MA